Table 3.
Significant canonical pathways from Ingenuity Pathway Analysis based on significant genes from region-based analysis, associated with high vs. low BTEX exposure.
| Ingenuity Canonical Pathways | p-Value | Proportion | Genes |
|---|---|---|---|
| GABA Receptor Signaling | 0.00219 | 0.023 | CACNA1H, GABRP, GNAO1 |
| Oxytocin In Brain Signaling Pathway | 0.00646 | 0.015 | CACNA1H, GNAO1, NLRP5 |
| Gustation Pathway | 0.00708 | 0.015 | CACNA1H, GABRP, TRPM4 |
| Assembly of RNA Polymerase III Complex | 0.02510 | 0.077 | BRF1 |
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 0.02570 | 0.009 | GNAO1, IL17RC, RIPK1 |
| G Beta Gamma Signaling | 0.02570 | 0.016 | CACNA1H, GNAO1 |
| Role of IL-17A in Psoriasis | 0.02690 | 0.071 | IL17RC |
| Endocannabinoid Neuronal Synapse Pathway | 0.03390 | 0.013 | CACNA1H, GNAO1 |
| Corticotropin Releasing Hormone Signaling | 0.03470 | 0.013 | CACNA1H, GNAO1 |
| Androgen Signaling | 0.04270 | 0.012 | CACNA1H, GNAO1 |
| IL-17A Signaling in Gastric Cells | 0.04900 | 0.039 | IL17RC |
BTEX, benzene, toluene, ethylbenzene, and xylenes; GABA, gamma-aminobutyric acid; IL, interleukin. The proportion column is the proportion of genes that were identified as significant that were present in the pathway.